BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2007

View Archived Issues

Phase I/II study of Oncohist in leukemia progresses

Read More

Activity seen with SNS-595 in acute leukemia patients

Read More

Preliminary phase I results with AT-9283 in hematological malignancies encouraging

Read More

Bupropion ameliorates methamphetamine dependence in some patients

Read More

New agents for musculoskeletal and connective tissue disorders claimed in recent patents

Read More

Novel therapeutic agents for Alzheimer's disease disclosed in recent patent literature

Read More

Update on Intra-Cellular Therapies' ITI-007/ITI-722 for schizophrenia and SMI

Read More

New agents for treating hematologic disorders reported in recent patents

Read More

Tissue-specific FAK gene deletion blocks mammary tumor progression

Read More

Ono enters license agreement with Nissan Chemical for new drug for thrombocytopenia

Read More

Novavax reports positive interim results from phase I/IIa trial of H5N1 vaccine

Read More

Nektar and Baxter expand agreement to develop PEGylated therapeutics for hemophilia

Read More

CFFT selects Triolex as drug candidate for lung inflammation linked with cystic fibrosis

Read More

Intercell submits BLA with FDA for Japanese encephalitis virus vaccine

Read More

Phase III clinical trial of Genitope's MyVax fails to meet primary endpoint

Read More

Peregrine gives update on its three lead clinical programs for bavituximab and Cotara

Read More

Actelion initiates RESTORA 1 phase III study of almorexant for primary insomnia

Read More

Corcept commences phase III Corlux trial for endogenous Cushing's syndrome

Read More

Pfizer receives FDA approvable letter for dalbavancin

Read More

GlaxoSmithKline and Santaris enter RNA antagonist alliance

Read More

Taxus Liberte drug-eluting stent receives CE mark for use in patients with diabetes

Read More

GlobeImmune initiates phase II GI-5005 trial in patients with chronic hepatitis C

Read More

ExonHit obtains approval to start phase II EHT-0202 trial in Alzheimer's disease

Read More

Galapagos enters strategic alliances with GlaxoSmithKline and Lilly

Read More

R-1507 antibody enters phase II sarcoma study

Read More

Phase II IPI-504 trial initiated in patients with non-small cell lung cancer

Read More

Conatus initiates phase II clinical trial for the treatment of hepatitis

Read More

VGX files IND for VGX-1027, a small molecule with antiinflammatory activity

Read More

Bazedoxifene receives second FDA approvable letter for prevention of osteoporosis

Read More

Noven reports FDA tentative approval of Stavzor valproic acid delayed release capsules

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing